For Doctors in a Hurry
- Researchers investigated the genomic and transcriptomic differences between primary and recurrent tumors in patients with high-risk localized renal cell carcinoma.
- This analysis utilized 754 primary and 80 recurrent tumor samples from a trial comparing adjuvant atezolizumab to a placebo.
- Recurrent tumors following atezolizumab treatment showed downregulation of major histocompatibility complex class I, which helps the immune system identify cancer.
- The researchers concluded that recurrent tumors exhibit distinct upregulation of cell proliferation and stromal biology signatures compared to primary tumors.
- These findings suggest a rationale for transitioning to vascular endothelial growth factor inhibition after the recurrence of tumors following immunotherapy.
Navigating the Molecular Evolution of Recurrent Renal Cell Carcinoma
While the incidence of kidney cancer remains stable or slightly increasing, mortality rates have declined by approximately 2% annually due to significant advances in systemic therapy [1]. For patients with high-risk localized disease, the surgical standard of care is often followed by adjuvant immunotherapy to delay recurrence, though clinical trial results in this setting have been notably heterogeneous [2, 3]. Currently, pembrolizumab remains the only immune checkpoint inhibitor with a clear recommendation for adjuvant use, as several other agents have failed to meet primary disease-free survival endpoints, including atezolizumab in the IMmotion010 trial which showed a hazard ratio of 0.93 (95% CI 0.75 to 1.15, p=0.50) [2, 4, 5]. Despite these interventions, many patients still experience disease relapse, and the optimal management of tumors that recur after exposure to checkpoint blockade remains a significant clinical challenge [6, 7]. A new study of 80 matched patient samples now provides a detailed characterization of how the genomic and transcriptomic landscape (the complete set of RNA transcripts produced by the genome) shifts between the primary tumor and the site of recurrence [8]. This analysis revealed that recurrent tumors exhibit an upregulation of signatures related to cell proliferation, fatty acid synthesis, and stromal biology (including the connective tissue matrix and fibroblasts that support tumor growth) compared to their primary counterparts [8].
The researchers analyzed the transcriptomic profiles (the patterns of gene expression) of 754 resected primary tumors from the IMmotion010 cohort at pre-treatment baseline to determine how they differ from established metastatic disease. This comparison is critical for clinicians because the molecular landscape of a localized tumor at the time of nephrectomy may dictate its future sensitivity to systemic therapies. The analysis revealed that resected primary tumors possessed a higher proportion of angiogenic transcriptomic signatures (gene expression patterns associated with the formation of new blood vessels) compared with published metastatic cohorts. Additionally, these primary tumors showed a higher proportion of small nucleolar RNA transcriptomic signatures, which are molecules involved in the regulation of the cell's protein synthesis machinery. Conversely, the primary tumors in this high-risk group exhibited distinct deficiencies in immune and structural markers when compared to metastatic benchmarks. The study found that resected primary tumors had a lower proportion of T-effector/proliferative signatures, which serve as markers of an active T-cell mediated immune response and rapid cell division. Furthermore, these tumors demonstrated a lower proportion of stromal/proliferative signatures, indicating a reduced presence of markers related to connective tissue involvement and associated cell growth. These findings suggest that primary high-risk renal cell carcinoma is characterized by a more prominent vascular and biosynthetic profile, while lacking the robust immune infiltration and stromal complexity typically seen in advanced metastatic disease.
Treatment-Induced Immune Evasion Mechanisms
To understand how adjuvant therapy influences the molecular evolution of renal cell carcinoma, the researchers conducted a detailed longitudinal analysis of tumor tissue collected at the time of nephrectomy and again upon disease recurrence. This investigation involved matched transcriptomic analyses performed on 80 primary versus recurrent samples, providing a high-resolution view of gene expression changes over time. To complement these findings, the authors also conducted matched genomic analyses (the study of the complete set of DNA mutations and structural variations) on 52 primary versus recurrent samples. By comparing these paired specimens, the study identified how the selective pressure of the immune system, particularly when augmented by checkpoint inhibition, alters the tumor's biological landscape. The molecular characteristics of recurrent tumors differed significantly based on whether patients had received the study drug or a placebo. In the control arm, tumors that recurred in placebo-treated patients demonstrated increased B cell signatures and increased macrophage signatures, suggesting a natural influx of these immune cell types during the progression of metastatic disease. However, a distinct and clinically relevant pattern emerged in the experimental arm. Tumors that recurred despite adjuvant atezolizumab showed downregulation of major histocompatibility complex (MHC)-I, which refers to the reduction of the cellular machinery required for the immune system to present antigens and allow T-cells to recognize and attack tumor cells. This loss of MHC-I expression represents a sophisticated immune evasion mechanism, as the tumor effectively becomes invisible to the adaptive immune system. For the practicing clinician, this finding provides a biological rationale for the observed resistance to subsequent immunotherapy and suggests that transitioning to vascular endothelial growth factor (VEGF)-targeted inhibition may be a more effective strategy for patients who progress after adjuvant checkpoint blockade.
Clinical Rationale for Sequential Therapy Selection
The observation that tumors recurring after adjuvant atezolizumab exhibit downregulation of major histocompatibility complex (MHC)-I provides a molecular explanation for why these cancers often fail to respond to subsequent rounds of immunotherapy. MHC-I molecules are essential proteins that present tumor antigens on the cell surface for recognition by cytotoxic T-cells. When a tumor reduces the expression of these proteins, it effectively hides from the immune system, rendering checkpoint inhibitors that rely on T-cell activation less effective. This specific mechanism of acquired resistance suggests that continuing with immune-based therapies may yield diminishing returns once a patient has progressed on an adjuvant programmed death-ligand 1 inhibitor. Because the loss of MHC-I creates a barrier to immune-mediated clearance, clinicians must look toward alternative pathways that do not depend on antigen presentation. The MHC-I downregulation in atezolizumab-treated recurrences suggests a potential rationale for transitioning to vascular endothelial growth factor (VEGF)-inhibition after adjuvant checkpoint inhibition. VEGF-targeted therapies, which inhibit the signaling proteins responsible for stimulating new blood vessel growth (angiogenesis), operate through a mechanism that remains viable even when the tumor has developed immune-evasive characteristics. By shifting the therapeutic focus from the immune microenvironment to the tumor's metabolic and structural requirements, physicians can target the established vascular pathways that support metastatic growth. While these findings require further clinical validation, they offer a biological framework for selecting second-line treatments in the setting of post-adjuvant recurrence.
References
1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA A Cancer Journal for Clinicians. 2023. doi:10.3322/caac.21763
2. Pal SK, Uzzo R, Karam JA, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.. Lancet (London, England). 2022. doi:10.1016/S0140-6736(22)01658-0
3. Bedke J, Albiges L, Capitanio U, et al. The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma.. European urology. 2023. doi:10.1016/j.eururo.2022.10.010
4. Monteiro F, Soares A, Rizzo A, et al. The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis.. Clinical Genitourinary Cancer. 2023. doi:10.1016/j.clgc.2023.01.005
5. Chatzkel J, Fishman M, Ramnaraign B, O'Malley P, Sonpavde GP. Approaches to Treating High Risk and Advanced Renal Cell Carcinoma (RCC): Key Trial Data That Impacts Treatment Decisions in the Clinic.. Research and reports in urology. 2024. doi:10.2147/RRU.S457287
6. Arrabal-Polo M, Gómez-Morón L, Gutierrez-Tejero F, Zambudio-Munuera A, Millán-Ramos I, Arrabal-Martín M. Adjuvant treatment in intermediate/high-risk clear cell renal cell carcinoma. Systematic review.. Actas Urológicas Españolas. 2025. doi:10.1016/j.acuroe.2025.501685
7. Sipra QR, Riaz I, Naqvi S, et al. Adjuvant immunotherapy in renal cell carcinoma: A living systematic review and network meta-analysis (NMA).. Journal of Clinical Oncology. 2023. doi:10.1200/jco.2023.41.6_suppl.694
8. Xu W, Rini BI, Albiges L, et al. Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.. European urology. 2026. doi:10.1016/j.eururo.2026.03.023
